Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.76 |
| ▸ | CASR | P41180 | 4/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.57 |
| ▸ | DRD1 | P21728 | 1/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29560 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2CASRPOLBSIGMAR1CYP3A4 | |
| SCHEMBL79765 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2CASRPOLBSIGMAR1CYP3A4 | |
| Hydrochloric Acid SCHEMBL27830673 | 0.98 | SMN1; SMN2 (0.79) | SMN1; SMN2CASRPOLBSIGMAR1CYP3A4 | |
| SCHEMBL27939948 | 0.98 | SMN1; SMN2 (0.73) | SMN1; SMN2CASRPOLBSIGMAR1CYP3A4 | |
| Hydrochloric Acid SCHEMBL5493749 | 0.98 | SMN1; SMN2 (0.79) | SMN1; SMN2CASRPOLBSIGMAR1CYP3A4 | |
| Hydrochloric Acid SCHEMBL9635019 | 0.98 | SMN1; SMN2 (0.79) | SMN1; SMN2CASRPOLBSIGMAR1CYP3A4 | |
| SCHEMBL11881252 | 0.96 | SMN1; SMN2 (0.70) | SMN1; SMN2CASRPOLBSIGMAR1CYP3A4 | |
| SCHEMBL14469578 | 0.96 | SMN1; SMN2 (0.82) | SMN1; SMN2CASRPOLBSIGMAR1CYP3A4 | |
| Diethylamine SCHEMBL27544555 | 0.91 | SMN1; SMN2 (0.65) | SMN1; SMN2CASRPOLBSIGMAR1CYP3A4 | |
| SCHEMBL11877401 | 0.90 | CASR (0.73) | SMN1; SMN2CASRPOLBSIGMAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 528 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4711367-A1 | PYRAZOLOPYRAZINE COMPOUND AND METHOD FOR PREPARING CRYSTAL FORM THEREOF | CMS Research & Development Pte. Ltd. (SG) | 2026-03-18 | — | — | EP | claimed |
| CN-120058681-A | Preparation method of high-optical-purity ritalst | 江苏东科康德药业有限公司 | 2025-05-30 | — | — | CN | claimed |
| US-20250078176-A1 | ENVIRONMENTAL ATTRIBUTES FOR NITROGEN CONTAINING CHEMICALS | BASF SE (DE) | 2025-03-06 | — | — | US | claimed |
| WO-2024235167-A1 | PYRAZOLOPYRAZINE COMPOUND AND METHOD FOR PREPARING CRYSTAL FORM THEREOF | 海南康哲美丽科技有限公司 | 2024-11-21 | — | — | WO | claimed |
| CN-111193069-B | Electrolyte for electrochemical device, method for preparing the same, and electrochemical device | 三星电子株式会社 | 2024-11-01 | — | — | CN | claimed |
| CN-118435582-A | Environmental attributes of nitrogen-containing chemicals | 巴斯夫欧洲公司 | 2024-08-02 | — | — | CN | claimed |
| CN-114195661-B | Preparation method of milobalin benzenesulfonate | 苏州楚凯药业有限公司 | 2023-12-22 | — | — | CN | claimed |
| CN-113330004-B | Differential solubility driven asymmetric conversion process for substituted 2H-chromene-3-carboxylic acids | 株式会社AskAt | 2023-11-17 | — | — | CN | claimed |
| WO-2023117926-A1 | ENVIRONMENTAL ATTRIBUTES FOR NITROGEN CONTAINING CHEMICALS | BASF SE (DE) | 2023-06-29 | — | — | WO | claimed |
| EP-3906232-B1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | ASKAT INC (JP) | 2023-05-10 | — | — | EP | claimed |
| WO-2008151170-A2 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-12-11 | — | — | WO | claimed |
| EP-1773802-A1 | ENANTIOSELECTIVE METHOD FOR SEPARING SUBSTITUTED 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006011047-A1 | ENANTIOSELECTIVE METHOD FOR SEPARING SUBSTITUTED 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-02 | — | — | WO | claimed |
| US-20060020022-A1 | Enantioselective separation method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | claimed |
| EP-1477486-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2004-11-17 | — | — | EP | claimed |
| US-6380400-B1 | DIMETHYLTHIOCARBAMIC ACID ESTER; VIRICIDES | FEDIJ VICTOR (US) | 2002-04-30 | — | — | US | claimed |
| US-6060617-A | REACTING AN ALKALI METAL HYDRIDE AND ALKALI METAL AMIDES WITH A SUBSTITUTED AMINE IN AN ETHER SOLVENT IN ABSENCE OF AN ELECTRON CARRIER TO PRODUCE AN ALKALI METAL AMIDE FREE OF ORGANIC CONTAMINANTS | FMC CORPORATION (US) | 2000-05-09 | — | — | US | claimed |
| WO-2000015625-A2 | METHODS OF MAKING DIHYDROPYRONE HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-03-23 | — | — | WO | claimed |
| EP-0845454-A1 | Method for the production of optically active cyclopropane derivatives | Ajinomoto Co., Inc. (JP) | 1998-06-03 | — | — | EP | claimed |
| WO-1994026708-A1 | OPTICALLY ACTIVE 3-(1-(ALKYLAMINO))ALKYL PYRROLIDINES | THE UPJOHN COMPANY (US) | 1994-11-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020022-A1 | Enantioselective separation method | SLC7A1, SLC10A1, DHCR7 | SMN1; SMN2 3170/4885CASR 1648/4885POLB 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.